Background: Initiation of re-entrant ventricular tachycardia (VT) involves complex interactions between activation (AT) and repolarization times (RT). The re-entry vulnerability index (RVI) is a recently proposed activation-repolarization metric designed to quantify tissue susceptibility to reentry.
Introduction
A significant challenge remains in the prediction of ventricular tachycardia (VT) circuits, especially in disorders of diffuse fibrosis or where the functional characteristics of the substrate play a critical role in the initiation of re-entry. This is reflected in Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC) and Brugada Syndrome (BrS), where fibrosis in the right ventricle can be especially difficult to image due to the diffuse epicardial nature of the disease and the limitations of magnetic resonance imaging (MRI) resolution in the thin RV free wall (1) (2) (3) . Both the prediction of ventricular arrhythmic events and targeting of ablation remain a demanding problem in these conditions due to the diffuse substrate and the presence of multiple VT morphologies or ventricular fibrillation (VF) leading to haemodynamic compromise.
Recently a novel spatial metric has been developed termed the Re-entry Vulnerability Index (RVI), used to locate regions of tissue susceptible to re-entry (4, 5) ( Figure 1) . The RVI is based on previous experimental studies which quantitatively assessed the likelihood of excitation wavefront-waveback interactions between two points spanning a line of conduction block following a premature stimulus (6) . The algorithm has subsequently been shown to accurately identify the region of a macro reentrant circuit in two animal models of ischaemia and a single clinical case of ischaemic cardiomyopathy (5) . Pilot simulations of RVI maps within a rabbit ventricular model (7) suggested that the metric was able to reliably identify exit sites associated with re-entrant circuits for different scar morphologies.
The aim of this study was to test the feasibility of RVI mapping in the RV for patients with BrS and ARVC. We hypothesised that (i) regions of low RVI may predict sites vulnerable to re-entry and therefore VT initiation and (ii) the global RVI may predict the propensity to clinically important ventricular arrhythmias to aid risk stratification in the prevention of sudden cardiac death.
Methods

Ethics statement
The research was approved by University College London Hospitals Ethics Committee A (08/H0714/97). Prior written informed consent to participate in this study was obtained from all participants.
Patient selection
38 patients aged 18-65 years were prospectively recruited to participate and informed consent was obtained. Inclusion criteria were a diagnosis of ARVC by modified task force criteria (including familial or genetic criteria) or a diagnosis of BrS based on type I ECG pattern (either spontaneous or provoked) with one of the following: documented VF, polymorphic VT, syncope or a family history of SCD. Patients with benign RV outflow tract (RVOT) ectopy or VT were used as a control cohort. All patients underwent detailed assessment with resting ECGs, signal averaged ECGs (SAECG) and echocardiography/MRI. Patients with a clinical suspicion of BrS underwent ajmaline provocation testing.
Following electrophysiological study (EPS), all patients had at least 50 months of follow up (mean = 112 ± 19 months). Patients were seen annually with clinical assessment, resting ECG, 24 hour tape or device interrogation and serial imaging if appropriate. A clinical arrhythmic event was defined as VF or haemodynamically unstable VT either terminating spontaneously or by anti-tachycardia pacing (ATP) /ICD shock.
The RVOT VT group had normal resting and SAECGs, only unifocal ectopy or VT, structurally normal hearts on echocardiogram/MRI and no family history of SCD. They were therefore classified as RV outflow tract focal VT. In order to minimize the likelihood of a patient with their first presentation of hitherto clinically silent cardiomyopathy or channelopathy being misassigned a diagnosis of benign RVOT ectopy, focal VT patients were excluded if they had a recurrence of ventricular ectopy/tachycardia post ablation.
Genetic testing
Whole blood samples were obtained from participating BrS and ARVC subjects. Genomic DNA was extracted using a commercially available DNA extraction kit (QIAamp DNA Blood mini kit, Qiagen).
ARVC cases were screened for mutations in desmoplakin, plakoglobin, plakophilin-2, desmoglein-2 and desmocollin-2, and BrS cases for mutations in SCN5A.
Electrophysiological mapping
The procedure for non-contact mapping has been previously described (8, 9) . The 64 electrode noncontact array (St Jude Medical, USA) was placed in the RVOT via the left or right femoral vein under conscious sedation and was positioned within 4cm of the endocardial surface to obtain accurate non-contact unipolar electrogram data. The geometry of the RV endocardium was created with a steerable quadrapolar mapping or ablation catheter.
Programmed stimulation was performed from the RV apex. 3 minutes of steady state pacing at 600 ms coupling intervals was followed by an electrical stimulation protocol, consisting of an 8 beat train of pulses (S1) at 600 ms coupling interval followed by a single, premature stimulus (S2). The S 1 S 2 coupling interval was reduced sequentially from 400 ms by 10 ms until ventricular refractoriness (VERP). A VT stimulation protocol followed, consisting of an 8 beat drivetrain from the RV apex at 600 and 400 ms baseline cycle length followed by S 2 until VERP or 200 ms coupling interval was reached. This was repeated for each baseline drivetrain adding an S 3 & S 4 .
Offline analyses
The non-contact mapping data consisting of 256 unipolar electrograms were collected with a recording bandwidth of 0-300 Hz in all cases and measurements made with a filter band width of 0.1-25 Hz. Electrograms were exported and analysed using semi-automated custom software running in Matlab (The Mathworks Inc., MA, USA) (10, 11) . During pacing, the time from pacing artefact to the steepest negative deflection (dV/dt min ) was used as the local activation time (AT). The classical (Wyatt) method was used to calculate the repolarisation time (RT) ( Figure 2 ) (12).
The RVI of each recording location i, RVI i , was calculated taking the minimum difference between RT at site i, RT i , and AT at neighbouring sites j comprised within a 20mm radius, AT j, :
Since vulnerability increases for lower RVI values, the definition of RVI i as the minimum difference between RT i and AT j ensured high spatial sensitivity to activation/repolarization abnormalities that may promote re-entry. The patient-specific location of the 256 ventricular sites from the clinical mapping system was then used to create an RVI colour map.
A global index of re-entry vulnerability, RVI G, was derived from the map by subtracting the median RVI from the 10 th percentile of the RVI distribution, P 10% (RVI i ):
This index is a robust version of the minimum RVI corrected to reduce cycle length dependency and it quantifies the global vulnerability of each patient.
For patients who developed VT during the VT stimulation protocol, the breakout site was identified as the earliest site of activation of the first VT beat (VT AT ). The distance (D min ) between the region of lowest RVI (including the bottom 5% of all RVI values) and the region of earliest activation during VT (including sites that activate within 5 and 20 mm from the site of earliest activation) was computed for each patient.
In order to provide consistent RVI measurements between hearts, for RVI G calculations the unipolar electrograms of a single S2 beat with approximately the same S 1 S 2 coupling interval (348 ± 17 ms) for each patient were used. For D min calculations where region of lowest RVI within each heart was of primary interest, the S 2 or where applicable S 3 beat immediately preceding VT initiation was used.
Results
Patient demographics
Demographics of all study subjects (13 BrS In the ARVC patients, 1 had episodes of sustained VT at presentation, 7 were diagnosed after investigation for palpitations and 3 were diagnosed through family screening. As well as the patient with clinical VT at presentation, another 5 patients had episodes of symptomatic VT during follow-up that was either sustained in patients without a device (n=2), or treated by ICD by ATP (n=3). Four patients (36%) had a positive VT stimulation study; all 4, plus a further 2 who had been negative at EPS, were the patients with clinical events. Five (45%) ARVC patients had an ICD; this included the patient with VT on presentation who was implanted as secondary prevention. Four others had primary prevention devices.
Localisation of VT breakout
In 6 BrS (46%) and in 4 ARVC (36%) patients, VT was induced during the VT stimulation protocol. A consistent feature seen in all cases was progressive slowing of conduction, followed by formation of an arc of functional conduction block on the RVOT endocardium. Lines of functional block evolved on a beat-to-beat basis. In 5 cases, the VT then degenerated to VF. Figure 3 shows an example of a BrS patient with initiation of VT after development of an arc of functional block during a VT stimulation study (subject 6). Patients were followed up for 112 ± 19 months. Those with clinical VT events had lower RVI G than those without VT (-54.5 ± 13.5 ms vs -36.2 ± 8.9 ms, p=0.002) or than those with focal VT (-30.6 ± 11.5 ms, p=0.001) ( Figure 5 ). Clinical events in our cohort included VF (2), haemodynamically unstable VT that terminated spontaneously (4) or was successfully treated by ICD with antitachycardia pacing (ATP) (3).
Discussion
The results of this study show that RVI, a metric based on relative local ATs and RTs, can be employed in the analysis of re-entrant arrhythmias occurring in ARVC and BrS patients. The algorithm localizes regions of high susceptibility to conduction block and re-entry, with lowest RVI values identifying the breakout of re-entrant but not focal arrhythmias and it associates low global RVI with a propensity for clinically significant ventricular arrhythmias. This was identified rapidly utilising non-contact mapping.
The identification of optimal targets for catheter ablation of scar-related VT remains a significant challenge. Catheter ablation therapies usually target the exit (or entry) site of the slow-conducting isthmuses of viable myocardium that often transect dense scar (13, 14) . However, accurate identification of the exit sites often requires VT induction, increasing the risk of the procedure as the VT may not be haemodynamically tolerated. The VT may also be difficult to induce or sustain, and may be mechanistically different to spontaneously occurring clinical VT. Voltage-mapping or detection of fractionated electrograms is frequently used to locate the isthmus region, but these techniques do not consider the repolarisation landscape around the scar and consequently find it difficult to identify the critical exit sites forming part of the re-entrant circuit, often leading to later recurrence. Furthermore, due to the often extensive nature of scar, large areas of ventricular myocardium are ablated using a "substrate based" approach leading to long procedures and risking increased myocardial damage. There is therefore a strong case for using a novel functional as opposed to anatomical substrate mapping technique incorporating both AT and RT information to predict sites of VT breakout without inducing VT. This could be further enhanced utilising a noncontact mapping approach to globally interrogate the ventricle. In our study, sites of lowest RVI did not correspond to the site of VT breakout in focal VT. This is in keeping with a mechanism of cAMP mediated triggered activity as opposed to localised re-entry (15) .
Increasingly, ablation is being used as a treatment option of inherited arrhythmic conditions. The majority of patients presenting with VT secondary to BrS and ARVC tend to have complex scar morphologies with patchy fibrosis and a number of different conduction pathways/channels that may support re-entrant circuits with multiple potential exit sites (16) (17) (18) (19) 2) . However, previous work from our group has shown that both BrS and ARVC are distinguished by marked decremental conduction delays even in the absence of detectable fibrosis on imaging, indicating that functional electrophysiological changes are critical to the initiation of VT in these patients, especially early in the disease process (20) (21) (22) . The proposed methodology can successfully identify exit sites in these conditions corresponding to the induced re-entrant VT circuits.
A further source of contention is risk stratification for the inherited arrhythmic conditions. SCD is often the first evidence of disease; therefore, identification of patients at highest risk is of utmost importance. Autopsy series and observational studies have reported a number of independent predictors of adverse outcomes in ARVC, in particular a prior history of sustained VT/VF and RV or LV dysfunction (23, 24) ; however these often occur late in the disease. Other potential risk factors with limited evidence include QRS fragmentation (25) , fragmented electrograms (26), extent of T-wave inversion (27) and precordial QRS amplitude ratio (25) . Recently AF, syncope, strenuous exercise after diagnosis, haemodynamically tolerated monomorphic VT and male sex have been reported as important risk factors for life threating arrhythmia (28) . There is conflicting data regarding the role of an electrophysiology study in risk stratification of SCD in ARVC (21) (22) (23) . Similarly, while the high-risk
BrS patient is recognized through aborted SCD or unexplained syncope (29) , risk stratification in asymptomatic patients is ill-defined, with inconsistent results from both non-invasive and invasive prognostic tests. These include spontaneous type 1 pattern, SCN5A mutation, syncope, family history of SCD, inducible arrhythmias, VERP < 200ms, QRS fragmentation, history of atrial fibrillation, lead I S-wave amplitude and duration (29) (30) (31) .
It is logical that a metric which incorporates both repolarisation and conduction changes may accurately reflect the potential for arrhythmogenesis in both these conditions. The RVI algorithm was able to distinguish between patients with ARVC and BrS who had haemodynamically 
Limitations
We paced from the RV apex; however, it is known that if the pacing site is changed, this may shift activation and repolarisation (11) and may in some cases shift exit sites for VT. Simulations in ischaemic cardiomyopathy have demonstrated that the RVI map may also change (7) and criteria for the selection of optimal pacing site should be identified in further studies. Our study population was relatively small, and to enable clinical translation, prospective testing in a larger cohort would be necessary to enable clinical translation and demonstrate its superiority over other common substrate mapping procedures. This is the subject of ongoing work. VT circuits were mapped in this study with non-contact activation maps; confirmation of the VT isthmus by entrainment was not possible as the VTs were haemodynamically unstable.
Conclusions
RVI mapping has the potential to significantly advance both risk stratification and VT ablation therapy in ARVC and BrS, where inducibility of VT at EPS remains highly contentious and additional risk markers are needed, and may provide specific ablation targets for non-inducible VT without the need for full substrate ablation.
Perspectives
Competency in Medical Knowledge: Unidirectional block and re-entry are the major determinants of VT initiation. VTs are often unstable and difficult to map sequentially due to multiple morphologies and haemodynamic compromise-employing a new metric (RVI) to predict sites of re-entry from local conduction and repolarisation parameters without inducing VT identifies the isthmus of VT and predicts probability of future events in ARVC and BrS.
Translational Outlook: Utilising conduction and repolarisation parameters without having to induce VT has important implications in identifying sites for focused ablation and risk stratification for ICD implantation. This approach needs to be evaluated in a prospective randomised study. Tables   Table 1 . Table showing demographics of study participants. RWMA = regional wall motion abnormalities, MR = mitral regurgitation, TR = tricuspid regurgitation, LV = left ventricle. Figure 1 . The time interval between the arrival of the wave at the exit site and the regaining of excitability (repolarisation) of the healthy tissue just proximal to it is a critical factor in determining the success of such a circuit to block or sustain re-entry. Patients with ARVC/BrS with inducible VT had significantly lower RVI G than those with no VT or than patients with focal VT.
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